multipl
sclerosi
cnsdirect
inflammatori
diseas
character
destruct
myelin
sheath
axon
loss
immun
cell
infiltr
perivascular
immun
cell
infiltr
found
activ
multipl
sclerosi
lesion
domin
lymphocyt
antigenpres
cell
lymphocyt
sospedra
martin
mcfarland
martin
pathogen
contribut
lymphocyt
multipl
sclerosi
extens
document
support
associ
suscept
multipl
sclerosi
major
histocompat
complex
mhc
ii
gene
eber
et
al
hain
et
al
sawcer
et
al
oksenberg
hauser
well
data
demonstr
transfer
diseas
myelinreact
lymphocyt
anim
model
multipl
sclerosi
experiment
autoimmun
encephalomyel
eae
regard
studi
eae
shown
crucial
role
lymphocyt
initi
progress
eae
becher
et
al
langrish
et
al
kebir
et
al
kroenk
et
al
stromn
et
al
meanwhil
littl
known
phenotyp
origin
rout
entri
lymphocyt
found
multipl
sclerosi
eae
lesion
exact
role
lymphocyt
autoimmun
cn
inflamm
remain
controversi
recent
evid
support
pathogen
protect
role
lymphocyt
multipl
sclerosi
eae
favour
pathogen
contribut
lymphocyt
oligoclon
expand
cell
detect
demyelin
multipl
sclerosi
tissu
babb
et
al
suggest
cn
antigen
reactiv
lytic
function
cell
also
found
close
associ
demyelin
axon
multipl
sclerosi
brain
tissu
neumann
et
al
cell
shown
interact
neural
cell
manner
saikali
et
al
recent
sever
group
also
develop
model
lymphocytedepend
eaelik
diseas
husebi
et
al
sun
et
al
cabarroca
et
al
zehntner
et
al
saxena
et
al
includ
induc
transfer
myelin
basic
myelin
oligodendrocyt
glycoprotein
mog
lymphocyt
anim
respect
husebi
et
al
sun
et
al
moreov
cabarroca
et
al
abl
induc
eaelik
diseas
transfer
haemagglutininspecif
lymphocyt
anim
overexpress
haemagglutinin
oligodendrocyt
demonstr
lytic
capac
cnsinfiltr
lymphocyt
convers
sever
report
indic
lymphocyt
could
play
regulatori
role
protect
diseas
develop
jiang
et
al
koh
et
al
fries
fugger
linker
et
al
york
et
al
includ
find
microglobulindefici
mice
exhibit
significantli
sever
eae
wildtyp
mice
linker
et
al
moreov
jiang
et
al
demonstr
lymphocyt
abl
dictat
phenotyp
lymphocyt
peripheri
eae
mice
induc
cell
addit
myelin
basic
proteininduc
eae
model
lymphocyt
downregul
pathogen
myelin
basic
proteinreact
lymphocyt
clone
jiang
et
al
also
lymphocyt
shown
prevent
diseas
relaps
jiang
et
al
koh
et
al
final
transfer
lymphocyt
mice
suppress
induct
eae
inhibit
ongo
eae
cytotoxicsuppressor
mechan
york
et
al
therefor
exact
contribut
lymphocyt
patholog
multipl
sclerosi
eae
remain
unresolv
physiolog
condit
limit
number
peripher
blood
immun
cell
cross
endotheli
cell
barrier
bbb
mening
vessel
process
call
immun
surveil
cn
sospedra
martin
inflammatori
process
mening
bbbendotheli
cell
amplifi
migrat
immun
cell
cn
parenchyma
multistep
process
involv
selectin
chemokin
receptor
cell
adhes
molecul
springer
leucocyt
first
undergo
e
pselectinmedi
roll
along
surfac
endotheli
cell
kube
ward
follow
chemokinemedi
activ
firm
adhes
endothelium
engelhardt
ransohoff
bbbendotheli
cell
glial
cell
import
sourc
proinflammatori
chemokin
rant
ifergan
et
al
requir
lymphocyt
monocyt
recruit
cn
ransohoff
et
al
engelhardt
ransohoff
mahad
et
al
lastli
importantli
upon
activ
proinflammatori
cytokin
bbbendotheli
cell
express
cell
adhes
molecul
intercellular
adhes
molecul
icam
vascular
cell
adhes
molecul
vcam
activ
leucocyt
cell
adhes
molecul
alcam
mediat
least
part
adhes
process
transmigr
leucocyt
cn
interact
integrin
leucocyt
functionassoci
antigen
lfa
late
antigen
vla
respect
greenwood
et
al
wong
et
al
biernacki
et
al
prat
et
al
cayrol
et
al
despit
ongo
controversi
role
lymphocyt
multipl
sclerosi
eae
exact
phenotyp
lymphocyt
found
inflam
brain
molecular
mechan
use
lymphocyt
access
target
organ
remain
incomplet
understood
current
studi
demonstr
human
mous
lymphocyt
inflam
cn
compart
mostli
effector
memori
lymphocyt
provid
evid
effector
memori
lymphocyt
better
propens
migrat
across
human
bbbendotheli
cell
noneffector
memori
cell
show
earli
eae
lymphocyt
infiltr
cn
display
aggress
function
granzym
b
interferon
ifn
lymphocyt
lymphocyt
migrat
faster
across
human
mous
bbbendotheli
cell
vitro
vivo
respect
final
show
migrat
lymphocyt
across
bbb
mainli
depend
integrin
vitro
vivo
seventeen
untreat
patient
multipl
sclerosi
diagnos
accord
mcdonald
criteria
mcdonald
et
al
healthi
volunt
includ
studi
forti
millilitr
blood
ml
csf
collect
patient
multipl
sclerosi
cell
phenotyp
analysi
inform
consent
approv
local
ethic
committe
given
patient
blood
csf
collect
local
ethic
approv
mean
age
patient
multipl
sclerosi
healthi
control
year
year
respect
patient
multipl
sclerosi
diseas
durat
last
year
relaps
rate
year
respect
cn
tissu
obtain
tempor
lobe
resect
specimen
young
adult
undergo
surgeri
treatment
intract
epilepsi
inform
consent
ethic
approv
given
prior
surgeri
ethic
approv
number
bh
bbbendotheli
cell
isol
nonepilept
materi
accord
publish
protocol
ifergan
et
al
kebir
et
al
cayrol
et
al
brief
mening
remov
cortic
subcort
white
matter
materi
minc
resuspend
ph
phosphatebuff
salin
pb
wash
sever
time
remov
blood
cn
materi
homogen
use
five
stroke
loosefit
dounc
homogen
g
filter
pore
size
mesh
bsh
thompson
filtrat
pass
twice
pore
size
mesh
collect
treat
collagenas
type
iv
mgml
sigma
min
inactiv
foetal
bovin
serum
sigma
filtrat
spun
plate
vv
gelatinco
sixwel
plate
endotheli
cell
cultur
media
compos
cell
cultur
media
invitrogen
supplement
vv
foetal
bovin
serum
vv
human
normal
serum
endotheli
cell
growth
supplement
sigma
atmospher
two
day
initi
plate
well
wash
twice
pb
remov
nonadher
cell
fresh
media
ad
day
coloni
endotheli
cell
visibl
day
human
brain
endotheli
cell
microvessel
fraction
could
expand
tissu
cultur
flask
previous
demonstr
cell
express
factor
viii
von
willebrand
factor
ulex
agglutenen
bind
site
endotheli
antigen
suscept
tumour
necrosi
factor
tnf
induc
upregul
immunoreact
glial
fibrillari
acid
protein
undetect
confirm
absenc
contamin
astrocyt
smooth
muscl
cell
respect
prat
et
al
biernacki
et
al
wosik
et
al
astrocyt
cultur
human
cerebr
hemispher
foetus
week
gestat
obtain
human
foetal
tissu
repositori
albert
einstein
colleg
medicin
follow
approv
guidelin
canadian
institut
health
research
astrocyt
cultur
previous
describ
ifergan
et
al
complet
dulbecco
modifi
eagl
medium
invitrogen
supplement
vv
foetal
bovin
serum
express
glial
fibrillari
acid
protein
astrocytecondit
media
harvest
week
confluent
flask
ad
bbbendotheli
cell
cultur
media
specifi
eighti
millilitr
venou
blood
sampl
obtain
consent
healthi
donor
accord
institut
guidelin
peripher
blood
mononuclear
cell
isol
edta
anticoagul
blood
use
standard
amersham
pharmacia
biotech
densiti
gradient
centrifug
lymphocyt
purifi
peripher
blood
mononuclear
cell
use
magnet
cell
sort
miltenyi
biotec
accord
manufactur
instruct
lymphocyt
puriti
assess
flow
cytometri
use
isothiocyan
fitc
pe
apc
bd
bioscienc
cell
purifi
lymphocyt
popul
three
consent
healthi
donor
obtain
neg
select
use
antibodi
antip
immunobead
magnet
cell
sort
miltenyi
biotec
puriti
posit
select
cell
consist
confirm
flow
cytometri
bbbendotheli
cell
grown
primari
cultur
use
gener
vitro
model
human
bbb
previous
publish
ifergan
et
al
kebir
et
al
bbbendotheli
cell
plate
gelatinco
pore
size
boyden
chamber
collabor
biomed
product
densiti
cellswel
endotheli
cell
cultur
media
supplement
vv
astrocytecondit
media
h
order
allow
reach
confluenc
format
confluent
monolay
confirm
stain
well
solubl
tracer
diffus
ifergan
et
al
media
remov
replac
fresh
endotheli
cell
media
supplement
vv
astrocytecondit
media
freshli
purifi
human
lymphocyt
ad
upper
chamber
allow
migrat
h
across
bbbendotheli
cell
either
untreat
preactiv
h
uml
u
ngml
uml
u
ngml
biosourceinvitrogen
applic
migrat
experi
perform
presenc
block
antibodi
correspond
isotyp
use
clone
r
system
clone
r
system
antialcam
clone
r
system
antiplatelet
endotheli
cell
adhes
molecul
pecam
clone
biolegend
antimhci
clone
ebiosci
clone
r
system
antimonocyt
chemotact
protein
mcp
clone
r
system
clone
biolegend
clone
r
system
antibodi
appli
upper
chamber
min
prior
addit
immun
cell
h
cell
complet
migrat
bbb
cell
remain
upper
chamber
collect
count
profil
analys
flow
cytometri
migrat
experi
carri
differ
blood
donor
perform
triplic
seven
distinct
bbbendotheli
cell
prepar
endotheli
cell
death
assess
flow
cytometri
two
differ
prepar
brief
bd
bioscienc
ad
min
endotheli
cell
expos
purifi
cell
h
frequenc
dposit
cell
assess
gate
cell
human
cell
phenotyp
use
antibodi
specif
human
granzym
b
perforin
bd
bioscienc
mous
cell
phenotyp
use
specif
antibodi
mous
granzym
b
bd
bioscienc
cell
stain
min
wash
fluorescenceactiv
cell
sort
fac
buffer
contain
pb
contain
vv
foetal
bovin
serum
wv
sigma
cell
fix
permeabil
wv
paraformaldehyd
sigma
wv
saponin
hank
balanc
salt
solut
min
room
temperatur
intracellular
stain
perform
incub
cell
antibodi
granzym
b
perforin
min
ice
fac
buffer
contain
wv
saponin
follow
two
wash
resuspend
fac
buffer
cell
acquir
bd
lsrii
analys
use
bd
facsdiva
softwar
clone
bd
bioscienc
clone
ebiosci
stain
cell
activ
h
ionomycin
ngml
phorbol
pma
presenc
brefeldin
sigma
last
h
cocultur
cell
stain
surfac
marker
intracellular
stain
perform
eight
femal
mice
charl
use
induc
eae
activ
immun
mice
inject
subcutan
peptid
alpha
diagnost
intern
emulsifi
complet
freund
adjuv
supplement
mycobacterium
tuberculosi
difco
day
immun
ng
pertussi
toxin
administ
intraperiton
mice
inject
intraperiton
day
integrin
clone
monoclon
bd
bioscienc
isotyp
control
antibodi
clone
bd
bioscienc
two
independ
experi
perform
one
mice
per
group
anoth
mice
per
group
clinic
sign
eae
assess
daili
accord
follow
score
clinic
sign
diseas
limp
tail
hind
limp
weak
partial
hind
limb
paralysi
complet
hind
limb
paralysi
hind
fore
limb
paralysi
day
post
immun
three
four
mice
group
perfus
pb
follow
rapid
intracardiac
pb
perfus
spleen
spinal
cord
brain
remov
kept
ice
organ
separ
mash
except
brain
spinal
cord
pass
cell
strainer
make
singl
cell
suspens
splenocyt
treat
ammonium
chlorid
min
room
temperatur
lyse
red
blood
cell
cell
pass
anoth
cell
strainer
cn
cell
isol
densiti
gradient
centrifug
use
amersham
bioscienc
ab
number
lymphocyt
lymphocyt
determin
multipli
percentag
lineag
markerposit
cell
total
number
mononuclear
cell
isol
organ
anim
protocol
approv
institutionnel
de
protect
de
animaux
du
crchum
spleen
inguin
lymph
node
extract
day
immun
pass
cell
strainer
bd
bioscienc
cell
suspens
treat
erythrocyt
lyse
solut
ammonium
chlorid
resuspend
rpmi
supplement
foetal
bovin
serum
cell
cultur
vitro
day
without
stimul
presenc
recombin
mous
uml
recombin
mous
ngml
level
product
lymphocyt
evalu
flow
cytometri
assess
activ
cell
harvest
wash
hank
balanc
salt
solut
lymphocyt
purifi
use
magnet
cell
sort
miltenyi
biotec
accord
manufactur
instruct
lymphocyt
puriti
assess
flow
cytometri
purifi
lymphocyt
inject
intraperiton
recipi
mice
cellsmous
day
transfer
ng
pertussi
toxin
administ
intraperiton
mice
inject
intraperiton
day
either
integrin
clone
monoclon
bd
bioscienc
isotyp
control
antibodi
clone
bd
bioscienc
day
post
transfer
three
mice
group
perfus
pb
organ
recov
cnsimmun
cell
isol
percol
gradient
centrifug
number
lymphocyt
lymphocyt
cn
determin
multipli
percentag
lineag
markerposit
cell
total
number
mononuclear
cell
isol
cn
four
femal
mice
charl
river
infect
intracerebr
ic
neurotrop
neuroinvas
neurovirul
strain
mous
hepat
viru
mhv
gruslin
et
al
highest
nonleth
dose
plaqu
form
unit
administ
maxim
volum
gruslin
et
al
group
mice
inocul
steril
media
mock
day
post
infect
mice
inject
intraperiton
integrin
monoclon
bd
bioscienc
isotyp
control
antibodi
rat
bd
bioscienc
day
five
mice
group
perfus
pb
immun
cell
cn
isol
lymphocyt
number
determin
follow
method
eae
two
independ
experi
perform
five
mice
per
group
anim
protocol
approv
institutionnel
de
protect
de
animaux
de
linrsinstitut
armandfrappi
cipa
luxol
fast
blue
stain
perform
human
brain
tissu
specimen
obtain
three
patient
multipl
sclerosi
autopsi
mous
spinal
cord
specimen
previous
describ
kebir
et
al
section
show
acut
demyelin
lesion
activ
perivascular
mononuclear
cell
infiltr
select
three
donor
block
per
donor
mean
age
year
diseas
durat
rang
year
caus
death
pneumonia
n
urosepsi
n
barbitur
intox
n
cn
materi
eae
anim
collect
follow
rapid
intracardiac
pb
perfus
snapfrozen
liquid
nitrogen
human
murin
tissu
cryosect
thick
mount
superfrost
slide
thermo
scientif
fix
aceton
min
hydrat
pb
endogen
biotin
block
avidinbiotin
block
kit
invitrogen
requir
nonspecif
immunoglobulin
bind
block
serum
min
section
incub
h
primari
antibodi
dilut
serum
slide
wash
five
time
min
pb
vv
incub
follow
h
incub
secondari
antibodi
incub
done
room
temperatur
correspond
isotyp
use
control
immunostain
section
mount
gelvatol
contain
invitrogen
nuclear
stain
fluoresc
acquisit
carri
leica
confoc
microscop
leica
microsystem
imag
process
analysi
perform
leica
la
af
softwar
statist
analys
perform
use
prism
softwar
data
present
mean
sem
oneway
anova
perform
follow
bonferroni
multipl
comparison
post
hoc
test
experi
except
migrat
across
bbb
done
use
twoway
anova
without
post
hoc
test
p
consid
signific
lymphocyt
report
signific
cellular
constitu
activ
multipl
sclerosi
lesion
traugott
et
al
hauser
et
al
babb
et
al
saikali
et
al
found
csf
patient
multipl
sclerosi
jacobsen
et
al
thu
elect
compar
phenotyp
lymphocyt
present
csf
peripher
blood
patient
multipl
sclerosi
peripher
blood
mononuclear
cell
csf
cell
untreat
patient
multipl
sclerosi
immunostain
analys
flow
cytometri
note
enrich
effector
memori
lymphocyt
csf
compar
peripher
blood
patient
fig
establish
whether
lymphocyt
carri
effector
lytic
molecul
typic
ascrib
effector
memori
phenotyp
evalu
express
granzym
b
detect
increas
number
granzym
bexpress
cell
csf
compar
peripher
blood
collect
patient
fig
repeat
phenotyp
analysi
cell
obtain
patient
multipl
sclerosi
confirm
signific
increas
granzym
b
effector
memori
lymphocyt
csf
rel
peripher
blood
fig
p
collect
data
demonstr
presenc
accumul
enrich
potenti
lytic
effector
memori
lymphocyt
csf
multipl
sclerosi
patient
activ
diseas
order
gain
access
csf
accumul
cn
compart
peripher
blood
lymphocyt
need
cross
microvascular
structur
includ
bbbendotheli
cell
astrocyt
endfeet
pericyt
basement
membran
establish
whether
enrich
effector
memori
lymphocyt
observ
csf
patient
relaps
multipl
sclerosi
reflect
preferenti
migrat
peripher
blood
effector
memori
subset
whether
effector
memori
phenotyp
induc
transmigr
process
use
wellestablish
vitro
model
bbb
consist
primari
cultur
human
cn
microvascular
endotheli
cell
grown
presenc
astrocyt
factor
ifergan
et
al
kebir
et
al
upon
reach
confluenc
boyden
chamber
endotheli
cell
stimul
tnf
uml
two
cytokin
report
partak
multipl
sclerosi
pathogenesi
sospedra
martin
known
activ
endotheli
cell
calabresi
et
al
biernacki
et
al
sever
wash
remov
residu
cytokin
ex
vivo
lymphocyt
isol
peripher
blood
healthi
donor
allow
migrat
h
across
human
activ
bbbendotheli
cell
migrat
nonmigr
lymphocyt
collect
phenotyp
analys
flow
cytometri
lymphocyt
recov
lower
chamber
migrat
cell
consist
enrich
cell
compar
ex
vivo
lymphocyt
fig
supplementari
fig
consist
find
detect
higher
proport
granzym
b
lymphocyt
perforin
cell
fig
supplementari
fig
migrat
popul
nonmigr
ex
vivo
peripher
blood
cell
observ
differ
endotheli
cell
death
whether
endotheli
cell
cultur
presenc
absenc
cell
n
supplementari
fig
rule
possibl
migrat
result
damag
endotheli
monolay
caus
exposur
cytotox
lymphocyt
activ
lymphocyt
character
product
kaech
et
al
also
wellestablish
secret
lymphocyt
disrupt
endotheli
epitheli
barrier
kebir
et
al
human
two
proinflammatori
cytokin
known
express
memori
rather
naiv
lymphocyt
kebir
et
al
therefor
analys
capac
activ
human
bbbendotheli
cell
promot
recruit
cytokinesecret
lymphocyt
migrat
cell
popul
significantli
enrich
lymphocyt
express
alon
fig
supplementari
fig
percentag
cell
recov
upper
chamber
nonmigr
cell
significantli
differ
one
ex
vivo
peripher
blood
cell
rule
possibl
effector
memori
phenotyp
induc
lymphocyt
follow
transmigr
across
activ
endothelium
popul
sort
allow
migrat
separ
across
bbbendotheli
cell
interestingli
found
cell
migrat
avidli
across
activ
bbbendotheli
cell
cell
fig
similar
result
obtain
use
nonactiv
bbbendotheli
cell
data
shown
furthermor
small
percentag
lymphocyt
lost
surfac
express
marker
upon
migrat
across
bbbendotheli
cell
fig
confirm
enrich
effector
memori
lymphocyt
follow
vitro
migrat
lymphocyt
result
preferenti
recruit
across
bbbendotheli
cell
rather
induct
effector
phenotyp
noneffector
memori
popul
collect
find
demonstr
activ
human
bbbendotheli
cell
promot
recruit
effector
memori
lymphocyt
increas
propens
secret
granzym
b
perforin
order
valid
human
vitro
find
evalu
tempor
profil
lymphocyt
recruit
cn
experiment
model
neuroinflamm
overal
found
predomin
lymphocyt
within
lymphocyt
popul
cn
eae
mice
fig
howev
preclin
phase
eae
day
post
immun
score
lymphocyt
found
cn
effector
memori
lymphocyt
noneffector
memori
fig
symptomat
phase
diseas
proport
effector
memori
lymphocyt
increas
significantli
day
eae
score
fig
day
eae
score
equival
effector
memori
lymphocyt
fig
product
cytokin
granzym
b
lymphocyt
correl
effector
memori
phenotyp
day
post
immun
lymphocyt
cn
express
granzym
b
fig
fig
day
observ
mark
reduct
proport
granzym
b
lymphocyt
infiltr
cn
eae
mice
fig
throughout
cours
diseas
lymphocyt
repres
neglig
popul
cn
infiltr
cell
vivo
data
corrobor
vitro
observ
human
suggest
preferenti
recruit
effector
memori
lymphocyt
cn
compart
earli
stage
autoimmun
cn
inflamm
moreov
result
support
notion
eae
specif
popul
effector
memori
lymphocyt
access
cn
least
day
prior
recruit
develop
signific
popul
effector
memori
lymphocyt
fac
analysi
cn
homogen
allow
us
identifi
exact
locat
perivascular
versu
parenchym
white
grey
matter
effector
memori
lymphocyt
within
cn
compart
determin
whether
effector
memori
lymphocyt
found
csf
patient
multipl
sclerosi
also
present
brain
tissu
perform
situ
immunostain
granzym
b
distinct
postmortem
specimen
obtain
three
subject
multipl
sclerosi
sinc
effector
memori
popul
defin
absenc
low
express
marker
could
use
immunostain
focus
histolog
examin
luxol
fast
blue
stain
lesion
character
perivascular
infiltr
within
area
demyelin
previous
shown
kebir
et
al
cayrol
et
al
ifergan
et
al
infiltr
lymphocyt
rel
limit
lesion
lymphocyt
scatter
parenchyma
found
leptomening
previous
shown
hayashi
et
al
saikali
et
al
tripl
immunofluoresc
stain
demonstr
coexpress
granzym
b
lymphocyt
within
white
matter
infiltr
fig
leptomening
least
cell
per
lesion
analys
overal
found
ratio
lymphocyt
activ
multipl
sclerosi
lesion
n
lesion
three
donor
next
sought
confirm
find
mogimmun
eae
anim
histolog
examin
frozen
spinal
cord
section
obtain
four
eae
mice
show
infiltr
lymphocyt
posit
fig
c
posit
granzym
b
fig
lower
panel
fig
right
panel
data
support
notion
effector
memori
lymphocyt
infiltr
multipl
sclerosi
eae
lesion
carri
cytolyt
potenti
next
studi
mechan
lymphocyt
recruit
cn
compart
use
vitro
model
bbb
block
antibodi
direct
sever
adhes
molecul
chemokin
integrin
known
involv
leucocyt
transmigr
process
found
specif
blockad
alcam
mhci
integrin
alter
migrat
human
lymphocyt
across
rest
data
shown
across
tnf
bbbendotheli
cell
fig
howev
specif
blockad
integrin
use
monoclon
antibodi
significantli
reduc
migrat
lymphocyt
across
bbbendotheli
cell
compar
appropri
match
isotyp
control
monoclon
antibodi
fig
p
suggest
migrat
human
lymphocyt
across
human
bbbendotheli
cell
depend
integrin
independ
interact
confirm
role
integrin
migrat
lymphocyt
across
bbbendotheli
cell
evalu
effect
blockad
lymphocyt
recruit
cn
eae
use
eae
model
test
abil
integrin
antibodi
per
inject
intraperiton
day
post
immun
impact
recruit
lymphocyt
cn
compart
includ
perivascular
space
parenchyma
leptomening
previous
demonstr
theien
et
al
integrin
treatment
signific
impact
develop
clinic
sign
eae
fig
infiltr
immun
cell
cn
compart
fig
histopatholog
level
total
count
cnsinfiltr
lymphocyt
isol
day
reveal
predomin
cell
fig
howev
accord
vitro
human
data
detect
significantli
lower
number
lymphocyt
cn
compart
eae
mice
treat
integrin
antibodi
compar
treat
isotyp
monoclon
antibodi
fig
demonstr
direct
effect
integrin
antibodi
recruit
lymphocyt
first
evalu
express
infiltr
cell
found
cn
compart
eae
mice
day
post
immun
found
cnsinfiltr
lymphocyt
seen
isotypetr
mice
express
supplementari
fig
also
show
differ
number
lymphocyt
found
spleen
isotypetr
mice
integrintr
mice
day
supplementari
fig
demonstr
antibodi
treatment
deplet
lymphocyt
peripheri
final
order
demonstr
integrin
blockad
affect
lymphocyt
migrat
lymphocyt
migrat
blockad
mogreact
lymphocyt
transfer
naiv
recipi
mice
presenc
absenc
integrin
antibodi
lymphocyt
purifi
restimul
vitro
presenc
transfer
supplementari
fig
supplementari
data
isotyp
controltr
anim
develop
mild
diseas
averag
score
data
shown
anim
develop
clinic
sign
eae
score
one
six
anim
develop
score
furthermor
significantli
less
infiltr
lymphocyt
cn
compart
mice
treat
integrin
antibodi
compar
treat
isotyp
monoclon
antibodi
day
post
transfer
fig
p
number
lymphocyt
found
cn
compart
similar
activ
immun
adopt
transfer
group
suggest
activ
mogreact
lymphocyt
donor
anim
attract
bystand
naiv
lymphocyt
recipi
anim
cn
analysi
lymphocyt
popul
found
cn
recipi
mice
reveal
larg
portion
effector
memori
cell
supplementari
fig
carri
lytic
enzym
granzym
b
inflammatori
cytokin
respect
supplementari
fig
result
put
forward
import
contribut
integrin
recruit
lymphocyt
inflam
cn
compart
suggest
encephalitogen
lymphocyt
attract
naiv
bystand
lymphocyt
cn
one
essenti
role
lymphocyt
protect
host
viral
infect
evalu
whether
integrin
block
antibodi
could
impact
abil
lymphocyt
perform
antivir
surveil
cn
use
mous
model
cn
infect
coronaviru
inject
directli
brain
cn
infect
induc
migrat
brain
lymphocyt
express
low
level
stohlman
et
al
bergmann
et
al
peak
cn
immun
cell
infiltr
observ
day
infect
coincid
clearanc
infecti
viru
gruslin
et
al
hosk
lane
anticip
compar
uninfect
anim
lymphocyt
predomin
subset
found
cn
mice
cell
versu
cell
per
brain
ratio
three
lymphocyt
one
lymphocyt
fig
infiltr
lymphocyt
brain
mice
effector
memori
phenotyp
express
granzym
b
fig
c
granzym
b
express
higher
infiltr
lymphocyt
lymphocyt
express
compar
two
lymphocyt
subset
fig
data
compat
previous
publish
articl
import
immun
cell
respons
clearanc
surviv
mice
follow
mhv
infect
shown
sever
studi
use
scid
mice
wang
et
al
houtman
fleme
wu
perlman
evalu
role
integrin
immun
surveil
defenc
cn
viral
infect
integrin
antibodi
isotyp
inject
intraperiton
day
infect
anim
sacrif
day
integrin
antibodytr
mice
wors
clinic
phenotyp
moribund
compar
anim
receiv
isotyp
control
antibodi
observ
signific
reduct
lymphocyt
infiltr
cn
mice
treat
integrin
compar
control
anim
fig
p
respect
demonstr
direct
effect
integrin
antibodi
lymphocyt
recruit
cn
evalu
express
cell
found
cn
mice
day
infect
infiltr
lymphocyt
found
isotypetr
mice
express
supplementari
fig
also
show
differ
number
cell
found
spleen
isotypetr
mice
integrintr
mice
day
post
infect
supplementari
fig
demonstr
antibodi
treatment
deplet
lymphocyt
peripheri
data
confirm
critic
role
integrin
recruit
lymphocyt
subset
viral
infect
cn
compart
goal
current
studi
character
phenotyp
lymphocyt
found
cn
autoimmun
virusinduc
neuroinflammatori
event
identifi
molecular
determin
involv
traffick
lymphocyt
cn
compart
csf
brain
parenchyma
perivascular
space
leptomening
demonstr
herein
preferenti
migrat
effector
memori
lymphocyt
cn
compart
earli
cours
eae
coronaviru
infect
human
data
use
ex
vivo
csf
peripher
blood
sampl
patient
multipl
sclerosi
situ
immunostain
multipl
sclerosi
lesion
demonstr
major
lymphocyt
found
cn
compart
patient
multipl
sclerosi
csf
parenchyma
effector
memori
lymphocyt
addit
data
obtain
vitro
model
bbb
compos
primari
cultur
human
endotheli
cell
astrocytecondit
media
show
effector
memori
lymphocyt
better
suit
migrat
bbbendotheli
cell
vitro
human
bbb
assay
recapitul
entir
complex
neurovascular
unit
includ
pericyt
parenchym
basement
membran
data
present
herein
provid
strong
evid
effector
memori
lymphocyt
better
propens
migrat
bbbendotheli
cell
vascular
basement
membran
cell
subset
howev
model
fulli
recapitul
twostep
concept
develop
bechmann
et
al
immun
cell
must
migrat
second
layer
cn
perivascular
cell
glia
limitan
gain
access
brain
parenchyma
purpos
studi
prove
encephalitogen
potenti
effector
memori
lymphocyt
provid
evid
major
cnsinfiltr
lymphocyt
express
granzym
b
perforin
moreov
show
migrat
effector
memori
lymphocyt
cn
preced
effector
memori
lymphocyt
eae
induc
activ
immun
transfer
mogreact
lymphocyt
naiv
anim
promot
recruit
bystand
lymphocyt
recipi
anim
cn
final
demonstr
mogreact
lymphocyt
induc
clinic
form
mild
eae
averag
score
despit
recruit
equival
number
lymphocyt
studi
therefor
emphas
potenti
encephalitogen
activ
cnsinfiltr
lymphocyt
previous
propos
saikali
et
al
fries
fugger
provid
evid
lymphocyt
induc
eae
absenc
mogreact
lymphocyt
use
three
distinct
anim
model
neuroinflamm
human
vitro
transmigr
assay
also
clearli
demonstr
block
integrin
lead
signific
reduct
migrat
lymphocyt
across
cn
vascular
structur
surprisingli
lymphocyt
migrat
affect
block
interact
sinc
molecul
previous
shown
partak
recruit
variou
subset
leucocyt
cn
includ
lymphocyt
integrin
alcam
greenwood
et
al
prat
et
al
cayrol
et
al
monocytesdendrit
cell
integrin
alcam
seguin
et
al
cayrol
et
al
b
lymphocyt
integrin
alcam
alter
et
al
cayrol
et
al
eosinophil
integrin
gonlugur
efeoglu
neutrophil
integrin
choi
et
al
none
affect
lymphocyt
transmigr
conclud
lymphocyt
use
differ
restrict
molecular
mechan
gain
access
cn
remain
establish
whether
asid
integrin
addit
possibl
still
unidentifi
adhes
molecul
chemokin
pathway
involv
traffick
lymphocyt
cn
nevertheless
result
point
import
signific
effect
integrin
transendotheli
recruit
lymphocyt
cn
mice
human
use
experiment
vitro
bbb
system
data
also
suggest
consider
redund
molecular
rout
migrat
observ
numer
leucocyt
subset
ie
lymphocyt
monocyt
might
appli
lymphocyt
recruit
cell
target
organ
might
depend
restrict
array
adhes
molecul
natalizumab
human
monoclon
antibodi
direct
integrin
engelhardt
kappo
integrin
either
associ
integrin
form
integrin
form
heterodim
express
lymphocyt
human
mous
report
key
mediat
firm
adhes
migrat
peripher
blood
lymphocyt
antigenpres
cell
cn
vascular
structur
interact
andor
special
domain
matrix
protein
fibronectin
berlin
et
al
von
andrian
engelhardt
luster
et
al
eae
inject
mice
integrin
onset
symptom
prevent
develop
diseas
yednock
et
al
theien
et
al
patient
multipl
sclerosi
natalizumab
treatment
decreas
number
lymphocyt
csf
shown
benefici
effect
relaps
disabl
lesion
gadoliniumposit
lesion
tubridi
et
al
miller
et
al
oconnor
et
al
stuve
et
al
unfortun
integrin
therapi
link
increas
emerg
progress
multifoc
leucoencephalopathi
devast
demyelin
diseas
cn
caus
reactiv
human
jc
polyomaviru
kleinschmidtdemast
tyler
langergould
et
al
van
et
al
previous
known
occur
mainli
patient
hivaid
haematolog
malign
posttransplant
immunosupress
berger
cellular
immun
respons
mediat
antigenspecif
effector
memori
lymphocyt
jc
viru
shown
crucial
control
progress
multifoc
leucoencephalopathi
koralnik
et
al
du
pasquier
et
al
marzocchetti
et
al
although
specul
tempt
suggest
effect
integrin
therapi
effector
memori
lymphocyt
traffick
cn
observ
studi
could
explain
emerg
progress
multifoc
leucoencephalopathi
patient
treat
natalizumab
given
primari
function
effector
memori
lymphocyt
defend
organ
acut
persist
latent
viral
infect
data
provid
evid
immun
surveil
cn
compart
lymphocyt
significantli
hamper
integrin
therapi
overal
data
demonstr
effector
memori
lymphocyt
essenti
depend
integrin
migrat
across
bbbendotheli
cell
vitro
cn
compart
vivo
given
specif
subset
lymphocyt
known
involv
immun
surveil
target
organ
control
acut
persist
infect
postul
emerg
progress
multifoc
leucoencephalopathi
natalizumabtr
patient
aris
deficit
immunosurveil
cn
compart
immun
cell
transmigr
across
bbbendotheli
cell
repres
critic
step
initi
cnsdirect
immun
reaction
therefor
better
understand
mechan
involv
transmigr
specif
leucocyt
subset
critic
need
develop
therapi
aim
reduc
organtarget
inflamm
without
affect
immun
surveil
multipl
sclerosi
societi
canada
mssc
canadian
institut
health
research
cihr
mop
mop
ap
institut
infect
immun
cihr
canada
research
chair
neuroimmunovirolog
pjt
oper
grant
well
mssc
studentship
gm
ap
na
research
scholar
fond
de
la
recherch
en
du
hold
donald
pati
career
develop
award
mssc
ii
hold
studentship
mssc
hk
hold
cihr
studentship
jia
hold
postdoctor
fellowship
cihr
